All In Biotech

Drug Trial Radar · NCT00557921

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease

Last checked: Nov 19, 2026Latest source record: Jan 28, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 5,000 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

5,000

Planned (sponsor's estimate)

Start

Dec 2007

Primary completion

Nov 2009

Study completion Nov 2009

Sponsor

Lead sponsor
Cogentus PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 14, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer disease, in the setting of concomitant aspirin therapy. Antiplatelet therapy is an essential element of care for patients with atherothrombotic disease. Bleeding is a fundamental adverse effect of all antiplatelet drugs including aspirin, clopidogrel and dual antiplatelet regimens. The gastrointestinal tract is the most common site of bleeding related to antiplatelet therapy, typically in connection with peptic ulcer disease. Recently published studies suggest the use of clopidogrel carries a gastrointestinal bleeding risk similar to that of aspirin or non-aspirin non-steroidal anti-inflammatory drugs. Patients taking any two of these drugs (clopidogrel, aspirin and/or non-aspirin NSAIDs) are exposed to an even higher risk of bleeding and ulcer disease. Cogentus Pharmaceuticals is launching phase 3 trials of a novel combination product, CGT-2168, which has the potential to significantly reduce this problem and increase patient safety. CGT-2168 combines a standard dosage of clopidogrel and a gastroprotectant (omeprazole) in a once-daily pill that may reduce the likelihood of adverse gastrointestinal events.

Conditions

  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Coronary Artery Disease
  • Percutaneous Coronary Intervention

Interventions

  • CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirinDrug

    (CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)

  • Plavix (clopidogrel 75 mg) and aspirinDrug

    (CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of upper gastrointestinal clinical events, including gastroduodenal bleeding, symptomatic gastroduodenal ulcer, persistent pain with multiple gastric erosions, obstruction or perforationTime frame: Anticipated minimum of 48 weeks, up to end of study

Locations

491 sites in 16 countries. Site status is shown where the registry gives one.

  • Alabama Clinical Research Institute, Inc. (ACRI)

    Alexander City, Alabama

  • Alabama Clinical Therapeutics, LLC

    Birmingham, Alabama

  • Cardio-Thoracic Surgeons P.C.

    Birmingham, Alabama

  • Birmingham Heart Clinic, PC

    Birmingham, Alabama

  • John F Simmons , MD PC

    Geneva, Alabama

  • Clinical Research Consultants, Inc.

    Hoover, Alabama

  • The Heart Center, PC

    Huntsville, Alabama

  • Mobile Heart Specialists, PC

    Mobile, Alabama

  • Advanced Cardiac Specialists

    Mesa, Arizona

  • Redpoint Research

    Phoenix, Arizona

  • Cardiovascular Consultants, Ltd.

    Phoenix, Arizona

  • Cochise Clinical Research

    Sierra Vista, Arizona

  • Paradigm Clinical Research, Inc.

    Tucson, Arizona

  • Tri-Lakes Research

    Hot Springs, Arkansas

  • Michael A. Frais, Cardiologist, P.A.

    Hot Springs, Arkansas

  • NEA-Clinic Cardiology

    Jonesboro, Arkansas

  • Searcy Medical Center

    Searcy, Arkansas

  • Cardiology Consultants of Orange County

    Anaheim, California

  • Chest and Critical Care Consultants, A Medical Group

    Anaheim, California

  • Clinical Solutions Advantage

    Buena Park, California

  • Turns Institute for Clinical Research

    Castro Valley, California

  • Escondido Cardiology Associates

    Escondido, California

  • Accurate Clinical Trials, Inc.

    Laguna Hills, California

  • Therapeutic Research Institute of Orange County

    Laguna Hills, California

  • Kirtik Thaker MD

    Lakewood, California

  • Los Angeles Cardiology Associates

    Los Angeles, California

  • Merced Heart Associates

    Merced, California

  • Mission Internal Medical Group

    Mission Viejo, California

  • Altos Cardiovascular Associates

    Mountain View, California

  • Kenneth W. Carr, MD, Cardiology

    Oceanside, California

  • Rancho CucamongaClinical Trials

    Rancho Cucamonga, California

  • Inland Heart and Vascular Medical Associates

    San Bernardino, California

  • Ritchken and First

    San Diego, California

  • Rider Research Group

    San Francisco, California

  • Richard Levy, MD.

    San Francisco, California

  • Kaiser Permanente

    San Jose, California

  • Medical Helping Hands Research

    Santa Ana, California

  • Pacific Heart Institute

    Santa Monica, California

  • Radiant Research

    Santa Rosa, California

  • Harbor- UCLA Medical Center

    Torrance, California

Showing 40 of 491 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.